LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?
Open Access
- 3 March 2016
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 14 (3) , 214-225
Abstract
One of the most promising therapeutic targets for potential diseasemodifying treatment of Parkinson’s disease (PD) is leucine-rich repeat kinase 2 (LRRK2). Specifically, targeting LRRK2’s kinase function has generated a lot of interest from both industry and academia. This work has yielded several published studies showing the feasibility of developing potent, selective and brain permeable LRRK2 kinase inhibitors. The availability of these experimental drugs is contributing to filling in the gaps in our knowledge on the safety and efficacy of LRRK2 kinase inhibition. Recent studies of LRRK2 kinase inhibition in preclinical models point to potential undesired effects in peripheral tissues such as lung and kidney. Also, while strategies are now emerging to measure target engagement of LRRK2 inhibitors, there remains an important need to expand efficacy studies in preclinical models of progressive PD. Future work in the LRRK2 inhibition field must therefore be directed towards developing molecules and treatment regimens which demonstrate efficacy in mammalian models of disease in conditions where safety liabilities are reduced to a minimum.Keywords
This publication has 107 references indexed in Scilit:
- LRRK2 phosphorylates novel tau epitopes and promotes tauopathyActa Neuropathologica, 2013
- LRRK2 phosphorylates Snapin and inhibits interaction of Snapin with SNAP-25Experimental & Molecular Medicine, 2013
- Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease ModelsACS Chemical Neuroscience, 2012
- Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applicationsMovement Disorders, 2011
- Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S miceNeurobiology of Disease, 2011
- Membrane Localization of LRRK2 Is Associated with Increased Formation of the Highly Active LRRK2 Dimer and Changes in Its PhosphorylationBiochemistry, 2010
- Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant α-synucleinNeuron, 2009
- The Parkinson’s disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sitesBiochemical and Biophysical Research Communications, 2009
- Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control studyThe Lancet Neurology, 2008
- The Roc domain of leucine‐rich repeat kinase 2 is sufficient for interaction with microtubulesJournal of Neuroscience Research, 2008